For the most part, developing new medical technologies is a huge benefit to people. Take for instance the smart pill that the U.S. Food and Drug Administration (FDA) just approved, which is meant to monitor if patients are sticking to their medication schedule. While incredibly useful, it could also allow entities like the U.S. government to spy on its citizens even more intrusively than it does now.
No one likes to be spied on and yet this is exactly what concerned privacy groups are saying could happen with the digital pill that the FDA just approved for use. Called the Abilify MyCite, the pill comes with sensors that basically indicate if patients just took their medication, Futurism reports.
Abilify is a drug used to treat neurological conditions such as schizophrenia and bipolar disorders. The sensor is embedded in the pill, where it will send out a signal once it comes in contact with the stomach. This signal will be picked up by a patch on the patient’s left rib cage, which will then notify the monitoring personnel via the accompanying app.
The information that the sensors can send out can include the dosage, the exact time when the pill was taken, and even what the patient was doing at the time. Because of how intrusive the data mining process appears, groups concerned about potential abuses are speaking out. They are especially worried about potential punitive actions against patients who are committing what’s called nonadherence.
Basically, nonadherence or noncompliance refers to patients not taking their medication as they are supposed to. This leads to patients getting sicker, which then leads to higher medical costs due to the increased medical attention that they need. Apparently, this particular trend costs $100 billion a year, the New York Times reports.
There’s also the concern of medical professionals that a smart pill could lead to a feeling of coercion on the part of the patients. Subjects could feel pressured to take their medication because their doctors are monitoring them.


Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments
US Quantum Stocks Surge After $2 Billion Government Investment
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
EU Antitrust Probe Could Lead to Massive Google Fine Under DMA Rules 



